Immunotherapy for the Treatment of Cancer
Targeting multiple myeloma, triple-negative breast cancer, non-Hodgkin's lymphoma and more with highly potent biopharmaceutical drugs designed for targeted therapy.View Product Pipeline
GT Biopharma, Inc. a targeted immunotherapies company with close to market treatments for Central Nervous System diseases.
GT Biopharma, Inc. Announces Reverse Stock Spilt As Part of Oxis-Georgetown Planned Merger
Aug 21, 2017 • 12:00 EDT | Read More
GT Biopharma, Inc. (Oxis) Announces Corporate Update Conference Call With Incoming CEO Dr. Kathleen Clarence-Smith and Chairman Anthony Cataldo
Aug 7, 2017 • 8:00 EDT | Read More